Try a new search

Format these results:

Searched for:



Total Results:


Salvage Prostate Stereotactic Body Radiation Therapy After Definitive Cryoablation

Lischalk, Jonathan W; Katz, Aaron E; Blacksburg, Seth R; Mendez, Christopher; Sanchez, Astrid; Repka, Michael C; Witten, Matthew; Taneja, Samir; Lepor, Herbert; Haas, Jonathan A
Purpose/UNASSIGNED:Whole gland cryoablation is a guideline-approved definitive treatment for localized prostate cancer, and is being explored for partial gland ablation. However, there is limited data regarding management of cryoablation failures. Stereotactic body radiation therapy (SBRT) is a well-established method of primary treatment for prostate cancer. Here we review salvage SBRT after cryoablation failures. Methods and Materials/UNASSIGNED:A large database of patients treated with definitive SBRT was interrogated to identify those who underwent primary cryoablation. All patients were determined to have progressive disease based on a rising prostate specific antigen and/or postcryoablation biopsy. All patients were treated with SBRT over 5 treatment fractions using a robotic radiosurgical platform. Baseline cryoablation characteristics and pre- and posttreatment Expanded Prostate Cancer Index Composite questionnaires were analyzed. Acute and late toxicity was evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0. Cancer outcomes after salvage SBRT were stratified by disease and treatment characteristics. Results/UNASSIGNED:A total of 51 patients were identified who underwent cryoablation followed by salvage SBRT. The majority (47%) were found to have intermediate-risk disease at the time of SBRT salvage and most commonly were treated with 3500 cGy in 5 fractions to the prostate and seminal vesicles. Only 1 grade 3+ toxicity was identified. Patient-reported quality of life metrics after SBRT salvage followed prior patterns observed in the de novo SBRT setting. With a median follow-up of 40 months, 76% of the cohort demonstrated disease control. Median time to prostate cancer recurrence was 57.5 months, and recurrence was predominantly seen in patients with underlying high-risk disease. Conclusions/UNASSIGNED:This is the largest cohort of patients treated with any radiation therapy salvage after cryoablation and the first institution to report SBRT as a modality of salvage. Salvage SBRT after cryoablation results in low rates of high-grade toxicity, acceptable changes in patient-reported quality of life, and durable rates of long-term oncologic control.
PMID: 35647408
ISSN: 2452-1094
CID: 5232872

Stimulated raman histology allows for rapid pathologic examination of unprocessed, fresh prostate biopsies [Meeting Abstract]

Mannas, M; Jones, D; Deng, F -M; Hoskoppal, D; Melamed, J; Orringer, D; Taneja, S S
Introduction & Objectives: Delay between prostate biopsy (PB) and pathologic diagnosis leads to a concern of inadequate sampling and repeated biopsy. Stimulated Raman Histology (SRH) is a novel microscopic technique allowing real time, label-free, high-resolution microscopic images of unprocessed, un-sectioned tissue. We evaluated the accuracy of pathologist interpretation of PB SRH as compared to traditional hematoxylin and eosin (H&E) stained slides.
Material(s) and Method(s): Men undergoing prostatectomy were included in an IRB approved prospective study. 18-gauge PB cores, taken ex vivo from prostatectomy specimen, were scanned in a SRH microscope at 20 microns depth over 10-14 minutes using two Raman shifts: 2845cm-1 and 2930cm-1, to create SRH images. The cores were then processed as per normal pathologic protocols. 16 PB containing benign/prostate cancer histology were used as a SRH training cohort for 4 GU pathologists (1, 3, 2x >15 yrs experience), who were then tested on a set of 32 PB imaged by SRH and processed by traditional H&E. Sensitivity, specificity, and concordance for PCa detection on SRH relative to a consensus H&E were assessed. With a two-sided alpha level of 5%, it was calculated 32 SRH imaged biopsies would provide 90% power to detect concordance (k).
Result(s): PB cores were imaged in 2-3 separate strips (11-21 minutes) shown in Figure 1. In identifying any cancer, pathologists achieved moderate concordance (k=0.570; p<0.001) which improved when identifying GGG 2-5 PCa only (k=0.640, p<0001; sensitivity 96.4%; specificity 58.3%). In predicting Gleason score, the concordance for each pathologist varied from poor to moderate (k range -0.163 to 0.457). After individual assessment was completed a pathology consensus conference was held for the interpretation of the SRH PB. In identifying any prostate cancer, pathologists achieved near perfect concordance (k=0.925; p<0.001; sensitivity 95.6%; specificity 100%). When evaluating SRH in a consensus conference, the group prediction of Gleason score improved to moderate concordance (k=0.470; p<0.001). (Figure Presented) (Figure Presented)
Conclusion(s): SRH produces high quality microscopic images that allow for accurate identification of PCa in real-time without need for sectioning or tissue-processing. Individual pathologist performance varied highly suggesting potential for improvement with further training. Future SRH interpretation by convolutional neural network may further enhance GGG prediction
ISSN: 1873-7560
CID: 5184442

Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment

Jiang, Yu; Meyers, Travis J; Emeka, Adaeze A; Cooley, Lauren Folgosa; Cooper, Phillip R; Lancki, Nicola; Helenowski, Irene; Kachuri, Linda; Lin, Daniel W; Stanford, Janet L; Newcomb, Lisa F; Kolb, Suzanne; Finelli, Antonio; Fleshner, Neil E; Komisarenko, Maria; Eastham, James A; Ehdaie, Behfar; Benfante, Nicole; Logothetis, Christopher J; Gregg, Justin R; Perez, Cherie A; Garza, Sergio; Kim, Jeri; Marks, Leonard S; Delfin, Merdie; Barsa, Danielle; Vesprini, Danny; Klotz, Laurence H; Loblaw, Andrew; Mamedov, Alexandre; Goldenberg, S Larry; Higano, Celestia S; Spillane, Maria; Wu, Eugenia; Carter, H Ballentine; Pavlovich, Christian P; Mamawala, Mufaddal; Landis, Tricia; Carroll, Peter R; Chan, June M; Cooperberg, Matthew R; Cowan, Janet E; Morgan, Todd M; Siddiqui, Javed; Martin, Rabia; Klein, Eric A; Brittain, Karen; Gotwald, Paige; Barocas, Daniel A; Dallmer, Jeremiah R; Gordetsky, Jennifer B; Steele, Pam; Kundu, Shilajit D; Stockdale, Jazmine; Roobol, Monique J; Venderbos, Lionne D F; Sanda, Martin G; Arnold, Rebecca; Patil, Dattatraya; Evans, Christopher P; Dall'Era, Marc A; Vij, Anjali; Costello, Anthony J; Chow, Ken; Corcoran, Niall M; Rais-Bahrami, Soroush; Phares, Courtney; Scherr, Douglas S; Flynn, Thomas; Karnes, R Jeffrey; Koch, Michael; Dhondt, Courtney Rose; Nelson, Joel B; McBride, Dawn; Cookson, Michael S; Stratton, Kelly L; Farriester, Stephen; Hemken, Erin; Stadler, Walter M; Pera, Tuula; Banionyte, Deimante; Bianco, Fernando J; Lopez, Isabel H; Loeb, Stacy; Taneja, Samir S; Byrne, Nataliya; Amling, Christopher L; Martinez, Ann; Boileau, Luc; Gaylis, Franklin D; Petkewicz, Jacqueline; Kirwen, Nicholas; Helfand, Brian T; Xu, Jianfeng; Scholtens, Denise M; Catalona, William J; Witte, John S
Men diagnosed with low-risk prostate cancer (PC) are increasingly electing active surveillance (AS) as their initial management strategy. While this may reduce the side effects of treatment for prostate cancer, many men on AS eventually convert to active treatment. PC is one of the most heritable cancers, and genetic factors that predispose to aggressive tumors may help distinguish men who are more likely to discontinue AS. To investigate this, we undertook a multi-institutional genome-wide association study (GWAS) of 5,222 PC patients and 1,139 other patients from replication cohorts, all of whom initially elected AS and were followed over time for the potential outcome of conversion from AS to active treatment. In the GWAS we detected 18 variants associated with conversion, 15 of which were not previously associated with PC risk. With a transcriptome-wide association study (TWAS), we found two genes associated with conversion (MAST3, p = 6.9×10-7 and GAB2, p = 2.0×10-6). Moreover, increasing values of a previously validated 269-variant genetic risk score (GRS) for PC was positively associated with conversion (e.g., comparing the highest to the two middle deciles gave a hazard ratio [HR] = 1.13; 95% Confidence Interval [CI]= 0.94-1.36); whereas, decreasing values of a 36-variant GRS for prostate-specific antigen (PSA) levels were positively associated with conversion (e.g., comparing the lowest to the two middle deciles gave a HR = 1.25; 95% CI, 1.04-1.50). These results suggest that germline genetics may help inform and individualize the decision of AS-or the intensity of monitoring on AS-versus treatment for the initial management of patients with low-risk PC.
PMID: 34993496
ISSN: 2666-2477
CID: 5107432

Optimization of prostate biopsy - Micro-Ultrasound versus MRI (OPTIMUM): A 3-arm randomized controlled trial evaluating the role of 29 MHz micro-ultrasound in guiding prostate biopsy in men with clinical suspicion of prostate cancer

Klotz, Laurence; Andriole, Gerald; Cash, Hannes; Cooperberg, Matthew; Crawford, E David; Emberton, Mark; Gomez-Sancha, Fernando; Klein, Eric; Lughezzani, Giovanni; Marks, Leonard; Montorsi, Francesco; Salomon, Georg; Sanchez-Salas, Rafael; Shore, Neal; Taneja, Samir
BACKGROUND:Micro-ultrasound (microUS) is a novel ultrasound-based imaging modality which has demonstrated the ability to visualize prostate cancer. Multiparametric MRI/ultrasound (mpMRI/US) fusion has recognized advantages for the performance of prostate biopsy, however, it encompasses additional cost, time and technical expertise to performing prostate biopsy in comparison to conventional trans-rectal ultrasound biopsy. MicroUS may simplify and optimize this pathway. METHODS:OPTIMUM is a 3-arm randomized controlled trial comparing microUS guided biopsy with MRI/US fusion and MRI/MicroUS "contour-less" fusion. This trial will investigate whether microUS alone, or in combination with mpMRI, provides effective guidance during prostate biopsy for the detection of clinically significant prostate cancer (csPCa) for biopsy naïve subjects. 1200 subjects will be randomized. The economic impact will be evaluated. RESULTS:The rate of csPCa (defined as Grade Group 2 and above) in each arm will be compared. The primary hypothesis is non-inferiority of csPCa rate between the MRI/US fusion arm and the microUS-only arm (including the blinded microUS-only portion of the MRI/MicroUS arm). As a secondary objective, the csPCa rate between MRI/MicroUS fusion and MRI/US fusion arms will also be compared. Other secondary objectives include the increase in rate of patients diagnosed with csPCa due to each type of sample (mpMRI targeted, microUS targeted, systematic), the negative predictive value of each imaging modality, and a health economic analysis of the procedures in each arm. CONCLUSIONS:OPTIMUM will determine whether microUS can be used as an alternative to MRI/US fusion biopsy. The trial will also evaluate the efficacy of the simplified "contour-less" MRI/MicroUS fusion procedure. The adoption of the microUS technique will increase the proportion of men who can benefit from modern imaging-centric diagnostic strategies, and may help reduce variability, complexity, waiting time and cost within the diagnostic pathway.
PMID: 34728381
ISSN: 1559-2030
CID: 5140612

Stimulated Raman Spectroscopy as Rapid On-site Evaluation of Renal Neoplastic and Non-neoplastic Biopsies [Meeting Abstract]

Ren, Joyce; Mannas, Miles; Jones, Derek; Orringer, Daniel; Taneja, Samir; Deng, Fang-Ming
ISSN: 0023-6837
CID: 5243232

Stimulated Raman Spectroscopy as Rapid On-site Evaluation of Renal Neoplastic and Non-neoplastic Biopsies [Meeting Abstract]

Ren, Joyce; Mannas, Miles; Jones, Derek; Orringer, Daniel; Taneja, Samir; Deng, Fang-Ming
ISSN: 0893-3952
CID: 5243372

A workflow to generate patient-specific three-dimensional augmented reality models from medical imaging data and example applications in urologic oncology

Wake, Nicole; Rosenkrantz, Andrew B; Huang, William C; Wysock, James S; Taneja, Samir S; Sodickson, Daniel K; Chandarana, Hersh
Augmented reality (AR) and virtual reality (VR) are burgeoning technologies that have the potential to greatly enhance patient care. Visualizing patient-specific three-dimensional (3D) imaging data in these enhanced virtual environments may improve surgeons' understanding of anatomy and surgical pathology, thereby allowing for improved surgical planning, superior intra-operative guidance, and ultimately improved patient care. It is important that radiologists are familiar with these technologies, especially since the number of institutions utilizing VR and AR is increasing. This article gives an overview of AR and VR and describes the workflow required to create anatomical 3D models for use in AR using the Microsoft HoloLens device. Case examples in urologic oncology (prostate cancer and renal cancer) are provided which depict how AR has been used to guide surgery at our institution.
PMID: 34709482
ISSN: 2365-6271
CID: 5042602

Association Between Multiparametric Magnetic Resonance Imaging of the Prostate and Oncological Outcomes after Primary Treatment for Prostate Cancer: A Systematic Review and Meta-analysis

Stabile, Armando; Mazzone, Elio; Cirulli, Giuseppe O; De Cobelli, Francesco; Grummet, Jeremy; Thoeny, Harriet C; Emberton, Mark; Pokorny, Morgan; Pinto, Peter A; Taneja, Samir S
CONTEXT:The diagnostic accuracy of multiparametric magnetic resonance imaging (mpMRI) for prostate cancer (PCa) diagnosis has been extensively explored. Little is known about the prognostic value of mpMRI suspicion scores and other quantitative mpMRI information. OBJECTIVE:To systematically review the current literature assessing the relationship between pretreatment mpMRI and oncological outcomes after primary treatment for PCa to assess the role of mpMRI as a prognostic tool. EVIDENCE ACQUISITION:A computerized bibliographic search of MEDLINE/PubMed, EMBASE, Scopus, and the Cochrane Library CENTRAL databases was performed for all studies assessing the relationship between mpMRI and oncological outcomes after primary treatment for PCa. The review protocol is registered in the PROSPERO database (CRD42020209899). EVIDENCE SYNTHESIS:A total of six studies were included. Reliable evidence is still limited in this field. The Prostate Imaging-Reporting and Data System (PI-RADS) score was an independent predictor of biochemical recurrence (BCR) after radical prostatectomy (RP) in the majority of the studies included. The tumor volume at mpMRI was not significantly associated with BCR after RP for PCa. Data on disease progression and PCa-specific mortality are limited. Heterogeneity among the studies was substantial. CONCLUSIONS:The review shows that PI-RADS scores provide information on the future likelihood of cancer recurrence or progression, at least for men undergoing RP. We are of the view that this information should be taken into account to identify men at higher risk of unfavorable outcomes. PATIENT SUMMARY:A higher Prostate Imaging-Reporting and Data System score for magnetic resonance imaging of the prostate seems to be positively associated with oncological failure in prostate cancer and should be incorporated into future risk models.
PMID: 33384275
ISSN: 2588-9311
CID: 5154202

Making a case "for" focal therapy of the prostate in intermediate risk prostate cancer: current perspective and ongoing trials

Wang, Alex Z; Lebastchi, Amir H; O'Connor, Luke P; Ahdoot, Michael; Mehralivand, Sherif; Yerram, Nitin; Taneja, Samir S; George, Arvin K; Sanchez-Salas, Rafael; Ward, John F; Laguna, Pilar; de la Rosette, Jean; Pinto, Peter A
Focal therapy is growing as an alternative management options for men with clinically localized prostate cancer. Parallel to the increasing popularity of active surveillance (AS) as a treatment for low-risk disease, there has been an increased interest towards providing focal therapy for patients with intermediate-risk disease. Focal therapy can act as a logical "middle ground" in patients who seek treatment while minimizing potential side effects of definitive whole-gland treatment. The aim of the current review is to define the rationale of focal therapy in patients with intermediate-risk prostate cancer and highlight the importance of patient selection in focal therapy candidacy.
PMID: 33388878
ISSN: 1433-8726
CID: 4994992

Making a case "for" focal therapy of the prostate in intermediate risk prostate cancer: current perspective and ongoing trials

Wang, Alex Z.; Lebastchi, Amir H.; O\Connor, Luke P.; Ahdoot, Michael; Mehralivand, Sherif; Yerram, Nitin; Taneja, Samir S.; George, Arvin K.; Sanchez-Salas, Rafael; Ward, John F.; Laguna, Pilar; de la Rosette, Jean; Pinto, Peter A.
ISSN: 0724-4983
CID: 4764342